YAKHAK HOEJI (약학회지)

The Pharmaceutical Society of Korea (대한약학회)
권호 표지

Pharmacokinetics of Cyclosporine in Rabbits with Carbon Tetrachloride and Bile Duct Ligation-induced Hepatic Disorder

사염화탄소 및 담도폐쇄 유발 간장장애 가토에서 싸이크로스포린의 약물동태

  • 발행 : 1998.04.01
Download PDF
⟨ Previous Next ⟩

초록

This study was attempted to investigate the pharmacokinetics of cyclosporine (10mg/kg, oral) in rabbits with $CCI_4$ and bile duct ligation-induced hepatic disorder. The area under the curve (AUC) of blood cyclosporine concentration versus time was significantly increased ($CCI_4$-induced hepatic disorder. Elimination rate constant (Kel) was significantly decreased (p<0.05, p<0.01) in rabbits with $CCI_4$ and bile duct ligation-induced hepatic disorder. Volume of distribution (Vdss) and total body clearance (CLtot) were significantly decreased (p<0.01) in rabbits with $CCI_4$-induced hepatic disorder. But Vdss was significantly increased (p4-induced hepatic disorder were 874ng/ml and 2.71 hr, respectively. Cmax and Tmax values in rabbits with bile duct ligation were 105ng/ml and 2.834 hr, respectively. From results of this experiment. It is desirable to do therapeutic drug monitoring of cyclosporine for effective treatment when the cyclosporine is administered to patients with liver disorder m clinical practice.

키워드

참고문헌

  1. Lancet v.1 Cyclosporine A to prevent graft versus host disease in man after allogenic bone marrow transplantation Powles, R.L.;Clink, H.M.;Spence, D.
  2. Lancet. v.11 Cyclosporine A initially as the only immunosuppressant in 34 recipients of cadaveric organs. 32 kidneys. 2 pancerases. and livers Calne, R.Y.;Rolles, K.;White, D.J.
  3. Transplantation Proc. v.21(suppl. 1) Cyclosporine in autoimmune disease Bach, J.F.
  4. Clin. Pharmacokinet. v.21 Drug absorption in gastrointestinal disease and surgery Gubbins, P.;Bertch, K.
  5. Br. J. Clin. Pharmaco. v.33 The absorption site of cyclosporine in human gastrointestinal tract. Beglinger, C.;Drewe, J.;Kissel, T.
  6. Transplantation Proc. v.38 Pharmacokinetics of intraveneous cyclosporine in bone marrow transplant patients Yee, G.C.;Keneddy, M.S.;Storb, R.;Thomas, E.D.
  7. Transplantation Proc. v.15 Cyclosporine: Pharmacokinetics, metabolism and drug interactions Wood, A.J.;Maurer, G.;Niederberger, W.;Beveridge, T.
  8. J. Pahrmacokinet. Biopharm. v.16 On the dose dependency of cyclosporine A absorption and disposition in healthy volunteers Reymond, J.P.;Steimer, J.L.;Niederberger, W.
  9. Am. Soc. Pharm. Experi. Ther. v.13 The pharmacokinetics of cyclosporine Ⅰ. Single dose and constant rate infusion studies in the rabbit Wni, W.M.;Sawchuk, R.J.
  10. Br. J. Clin. Pharmacol. v.29 The effect of food and bile acid administration on the relative bioacailability of cyclosporine Linholm, A.;Henricsson, S.;Daglqvist, R.
  11. Nephron v.53 Renal effect of trimetoprim in cyclosporine and azathioprine treated kidney allogafted patients Berg, K.J.
  12. Am. J. Medicine v.87(suppl 5A) Cyclosporine A pharmacokinetics in renal transplant patients receving ciprofloxacin Lang, J.;Villaine, J.F.;Garraffo, R.;Touraine, J.L.
  13. Transplant v.23 Interaction of cyclosporine and probucol in heart transplant recipient patient Sundarajan, V.
  14. Ann. Intern. Med. v.108 Interaction between cyclosporine and warfarin Snyder, D.S.
  15. Ttransplantation Proc. v.24 Ursodeoxycholic acid enhances the absorption of cyclosporine in a heart transplant patient with short bowel syndrome Gutzler, F.;Zimmeermann, R.;Ring, G.;Sauer, P.
  16. Transplantation Proc. v.20 Cyclosporine A pharmacokinetics in a cardiac allograft recipient jejumoileal bypass Knight, G.;Peric, M.;Duncan , J.;Frazier, O.;Cooley, D.
  17. Clin. Pharmaco. Ther. v.39 Pharmacokinetics of cyclosporine in patients with rheumatoid arthirtis Lesco, L.J.;Minor, J.;Yocum. D.;Emm, T.
  18. N. Engl. Med. v.322 Small bowel length and the dose of cyclosporine in children after liver transplantation Whitington, P.;Emond, J.;Broelsch, C.;Baker, A.
  19. Transplantation v.40 Individualization of cyclosporine therapy using pharmacokinetics and pharmacodynamic parameters Kahan, B.D.
  20. J. Pharm. Sci. v.83 Reduced inter and intrainindivisual variability in cyclosporine pharmacokinetics from a microculsion formation John, M.K.;Edgar, A.M.;Johannes, B.B.;Wolfgang, T.;Klaus, K.
  21. Yakkak Hoeji v.34 Pharmacokinetics of furosemide in rabbits with renal failure Choi, J.P.;Choi, T.M.;Lee, J.H.;Burm, J.P.
  22. Ther. Drug monit. v.7 Assessment of cyclosporine A in whloe blood and plasma in five patients with different gematocrits Agarwal, R.P.
  23. Computer Programs in Biomedicine v.16 LAGRAN program for area and moments in pharmacokinetic analysis Rocci, M.L.;Jusko, W.J.
  24. Clin. Phamacol. Ther. v.44 Pharmacokinetics and clinical tolerance of intraveneous and oral cyclosporine in the immediate postoperative period Morse, G.D.
  25. Transplatation Proc. v.18(suppl 5) Pharmacokinetics of cyclosporine in toxicological studies Donatsch, P.;Ryffel, B.
  26. Br. J. Clin. Pharmacol. v.24 Pharmacokinetics of cyclosporine influence of rate of constant intraveneous infusion in renal transplant patients Gupta, S.K.
  27. Clin. Pharmacokinet. v.16 Therapeutic drug monitoring of cyclosporine:practical applications and limitations Rodighieor, V.
  28. Clinical Chemistry v.36 Consensus dosument : Hawf's cay meeting on therpeutic drug monitoring of cyclosporine Barry, D.K.;Leslie, M.S.;David, H.;Johnston, A.
  29. Clin. Chem. v.31 Effect of hematocrit on cyclosporine in whole blood and plasma of renal transplant patients Rosano, T.G.
  30. Ther. Drug Monit. v.11 Intra0 and interindividual variability in the free fraction of cyclosporine in plasma in recipients of renal transplant Lindholm, A.
  31. Pharmol. Rev. v.19 Carbon tetrachloride hepatotoxicity Reckinagel, R.O.
  32. Biochem. Pharmacol. v.21 Effect of 3-methylchloanthrene induction of the $CCI_4$ induced changes in rat hepatic microsomal enzyme system Maynard, E.H.;Bittern, S.;James, R.G.
  33. Lab. Invest. v.59 Pathologic changes in the cytokeratin pericanalicular sheath in experimental cholestasis and alcoholic fatty liver Ohta, M.;Marceau, N.;French, S.W.
  34. J. Path. Bact. v.25 Disturbance of structure and function in the liver as the result of biliary obstrucion Cameron, G.R.;Hanson, S.M.
  35. Biochem. Biophys. Res. Comm. v.56 Reduced synthesis of hepatic microsomal cytochrorom P450 in the bile duct ligated rat Mackinnon, A.M.;Simon, F.R.
  36. Lancet v.2 Hypothesis: Cholestasis is the result of a hypoactive hypertropic smooth endoplasmic reticulum in the hepatocyte Schaffiner, F.;Popper, H.
  37. J. Biol. Chem. v.261 Characterization of rat and human liver microsomal cytochrome p-450 forms involved in nifedipine oxidation, aprototype for genetic polymorpism in oxidative drug metabolism guengerich, P.F.
  38. Transplatation Proc. v.22 Structure of cyclosporine and its metabolites Wenger, R.M.
  39. Transplatation Proc. v.18 Cyclosporine metabolites in human blood and renal tissue Rosano, T.G.
  40. Europ. J. Clin. Invest. v.5 Alteration of drug metabolism during cholestasis in man Carulli, N.;Manenti, F.;Gallo, M.